- Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a biopharmaceutical company, is set to be acquired by Angelini Pharma for approximately $4.10 billion, marking Angelini Pharma’s entry into the U.S. market.
- Following the acquisition announcement, Oppenheimer downgraded Catalyst Pharmaceuticals from “Outperform” to “Perform” due to the fixed acquisition price of $31.50 per share.
- The acquisition deal is currently under investigation by investor rights law firm Halper Sadeh LLC, examining whether Catalyst Pharmaceuticals’ board secured the best possible price for shareholders.
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on rare disease treatments, is set to be acquired by the Italy-based Angelini Pharma in a cash deal valued at approximately $4.10 billion. As highlighted by GlobeNewswire, this significant pharmaceutical acquisition marks Angelini Pharma’s entry into the U.S. market and strengthens its position in brain health.
Following the acquisition announcement, Oppenheimer, a prominent financial institution, has downgraded Catalyst Pharmaceuticals from “Outperform” to “Perform.” An Outperform rating means a stock is expected to do better than the market average, while a Perform rating suggests it will move in line with the market. The stock price was $31.23 at the time of the rating change. This analyst rating change reflects new market performance expectations.
The downgrade is linked to the fixed acquisition price of $31.50 per share that Angelini Pharma will pay. This price sets a cap on how high the stock can go, limiting its potential to outperform. The offer is a 28% premium over the stock’s 30-day volume-weighted average trading price as of April 22, 2026, indicating a substantial premium for shareholders in this merger and acquisition.
The deal is also facing scrutiny. As reported by Business Wire, investor rights law firm Halper Sadeh LLC is investigating the sale. The firm is examining whether Catalyst Pharmaceuticals’ board secured the best possible price for shareholders and fulfilled its fiduciary duties. A fiduciary duty is the board’s legal obligation to act in the shareholders’ best financial interests, particularly in a major corporate transaction.
